AVJ16

AVJ16 is a cancer cell migration inhibitor that targets the insulin-like growth factor 2 mRNA binding protein IGF2BP1 with a good affinity of Kd of 1.4μM. AVJ16 interferes with IGF2BP1 binding target mRNA to regulate gene expression and translation[1].

Product Specifications

CAS Number

[2775241-92-2]

UNSPSC

12352005

Target

Apoptosis; Insulin Receptor

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/avj16.html

Concentration

10mM

Purity

99.60

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(CC1)C2=CC3=C(OCO3)C=C2)C4=CC=C(C=C4)CN5C(CO)=CC6=C5C=CC=C6

Molecular Formula

C28H27N3O4

Molecular Weight

469.53

References & Citations

[1]Singh A, et al. Development of a Novel IGF2BP1 Inhibitor as Metastasis-Specific Therapeutic Agent[J]. European Journal of Cancer, 2022, 174: S104-S105.|[2]Wallis N, et al. AVJ16 inhibits the RNA binding protein IGF2BP1 in lung adenocarcinomas and prevents tumor growth in mice[J]. bioRxiv, 2024: 2024.08. 15.608038.